Cost-effective intervention in stroke.
A rigorous assessment of current practice in all branches of medicine is necessary to ensure that we are minimising the costs and maximising the effectiveness of management and treatment.  This is especially important in cerebrovascular disease which imposes a large burden of death; it is the third commonest cause of death after cancer and heart disease in most developed countries, and the commonest cause of long term disability on society.  Stroke consumes up to 5% of healthcare expenditure in developed countries, and costs can be expected to remain static or increase with an increase in the proportion of elderly (who are at high risk of stroke) in the community over coming decades.  This article reviews the epidemiology of stroke (risk factors, incidence, prevalence and the burden of disability and handicap), the various studies dealing with the community and individual costs of stroke, and the cost-effectiveness of interventions to prevent stroke such as control of hypertension, reduction in cigarette intake, encouragement of a healthy lifestyle, antiplatelet or anticoagulant therapy, and carotid endarterectomy.  Acute treatment of stroke remains an area of major potential therapeutic benefit, but no widely applicable therapy currently exists, although many treatments are being investigated. Rehabilitation after stroke is costly, but may result in significant reduction in disability and handicap with reduced need for long term institutional care.  The clinical implications of these studies and the potential for future research are also discussed.
Dunbabin
D
D
Flinders Medical Centre, Bedford Park, Australia.
D000368:Aged; D000925:Anticoagulants; D000959:Antihypertensive Agents / Q000191:economics; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D006233:Persons with Disabilities; D016894:Endarterectomy, Carotid; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D015994:Incidence; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors; D015995:Prevalence; D011379:Prognosis; D011788:Quality of Life; D016540:Smoking Cessation; D016896:Treatment Outcome